Braveheart Investment Group plc (AIM: BRH) provides the following update on Phasefocus and Paraytec, companies within the Group’s investment portfolio.
Trader’s Café with Zak Mir: A Week In Small Caps, Saturday 15th October 2022
Perhaps the best thing about the Government’s present woes as far as small caps are concerned is that we are already bumping along the bottom, or at least hope that
Sareum Holdings PLC (AIM:SAR) CTA application to MHRA and Corporate Update
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Poolbeg Pharma PLC (AIM:POLB) Commencement of trading on US OTCQB market
Poolbeg Pharma commences trading on OTCQB Market in the United States
Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason
First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza
Poolbeg Pharma PLC (AIM:POLB) 2021 Annual Report and 2022 AGM Notice
9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and
Braveheart Inv Group (AIM: BRH) Operational update
Braveheart Investment Group plc (AIM: BRH), provides the following update on its investment portfolio and strategy.
Poolbeg Pharma PLC (POLB.L) Confirmation of vaccine platform licence execution
31 January 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a capital-light clinical model, confirms that it has signed the licence
Braveheart Inv Group (BRH.L) Operational update on Paraytec
Braveheart Investment Group plc (AIM: BRH), is pleased to provide the following update on Paraytec, a company within the Group’s investment portfolio. Recent upgrades to the CX300 instrument indicate a
Poolbeg Pharma PLC (POLB.L) Exclusive license of RNA-based immunotherapy asset
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
Poolbeg Pharma (LSE:POLB) Year in (Video) Review 2021
Targeting the growing infectious disease market, we are developing multiple assets quickly to Phase II ready with plans to monetise early to Big Pharma. POLB spun out of Open Orphan